Last reviewed · How we verify
Genesa (ARBUTAMINE)
Genesa (Arbutamine) is a small molecule drug that targets the beta-1 adrenergic receptor. It was originally developed and is currently owned by a pharmaceutical company. Genesa is used for cardiac function studies and was FDA approved in 1997. The drug is off-patent and has no active generic manufacturers. As an off-patent drug, its commercial status is limited.
At a glance
| Generic name | ARBUTAMINE |
|---|---|
| Drug class | arbutamine |
| Target | Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1997 |
Approved indications
- Cardiac Function Studies
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |